Inspire Investing LLC Has $357,000 Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Inspire Investing LLC boosted its position in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 90.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 139,079 shares of the biopharmaceutical company’s stock after buying an additional 65,919 shares during the quarter. Inspire Investing LLC owned approximately 0.13% of Revance Therapeutics worth $357,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of RVNC. Quest Partners LLC acquired a new position in shares of Revance Therapeutics during the fourth quarter worth approximately $84,000. Certuity LLC acquired a new position in shares of Revance Therapeutics during the second quarter valued at about $26,000. Victory Capital Management Inc. bought a new stake in shares of Revance Therapeutics in the 4th quarter worth approximately $93,000. HighPoint Advisor Group LLC bought a new position in Revance Therapeutics in the fourth quarter worth $98,000. Finally, Clarity Capital Partners LLC bought a new position in shares of Revance Therapeutics during the 1st quarter worth about $59,000. Institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on RVNC shares. William Blair reissued a “market perform” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Piper Sandler downgraded Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. Stifel Nicolaus dropped their price target on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating for the company in a report on Friday, August 9th. Needham & Company LLC lowered Revance Therapeutics from a “moderate buy” rating to a “hold” rating in a research note on Tuesday, August 13th. Finally, StockNews.com began coverage on Revance Therapeutics in a research note on Sunday, September 15th. They issued a “hold” rating for the company. Ten analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $10.50.

Revance Therapeutics Trading Down 0.7 %

NASDAQ:RVNC opened at $5.81 on Friday. Revance Therapeutics, Inc. has a 1-year low of $2.30 and a 1-year high of $13.12. The firm has a market capitalization of $606.85 million, a price-to-earnings ratio of -1.60 and a beta of 1.00. The business’s 50-day moving average price is $5.33 and its two-hundred day moving average price is $4.28.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.12. The firm had revenue of $65.39 million for the quarter, compared to the consensus estimate of $66.30 million. During the same period in the previous year, the business earned ($0.80) EPS. The firm’s revenue was up 20.2% compared to the same quarter last year.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.